In contrast, although Łukasiewicz et al. supported the expression of ER, PR, HER2, and Ki-67 as predictive and potential prognostic factors, the updated review on breast cancer specified that patients with higher expression of these biomarkers are those who are usually present significantly better clinical outcomes [144]. The gene discussed is ERBB2; the disease is breast carcinoma.